intellia logo

“The thought that my efforts to advance our CRISPR technology give hope to patients suffering from life-threatening genetic diseases drives me to work every day.”

Chirag
Senior Associate Scientist, CMC
Bill, living with transthyretin amyloidosis, and his wife, Maura

“I get up every day to show our kids that life doesn’t stop with a diagnosis.”

Read more

“UKATPA’s objective is to raise awareness and give support to patients, caregivers and health care professionals.”

Vince
UKATPA Treasurer

Vince and David, friends and colleagues living with ATTR

“The biggest surprise to us was how many people have amyloidosis and don’t have anyone to talk to.”
– David, UKATPA Secretary

Read more

“Intellia provides the perfect combination of innovative science, great people and room for professional growth.”

Nicole
Senior Research Associate, Cell Therapy

“My father-in-law, Ben – or as Pam calls him, Benny – lost his battle with AML far too soon, which makes me especially proud to work for a company that is striving to provide curative treatments for that disease, among others.”

Stacey
Associate Director, Finance
Pam, whose husband passed away from acute myeloid leukemia

“Benny had a way of making everything OK. I miss his smile.”

Read more

“I like working at Intellia because I am challenged to think creatively and collaboratively. It’s rewarding to know our efforts are making an impact toward our goal of developing potentially life-changing therapies.”

Spencer
Senior Research Associate, DNA Repair

“Have you ever been in an environment full of intellectual people? Now combine that with CRISPR/Cas9. Greatness at full potential.”

Denisse
Associate Scientist, Mass Spectrometry


Press
Releases


Events &
Presentations


Leadership

Programs

Each one of us together for patients.

Using a modular approach, we optimize the necessary therapeutic components so they can be used and combined in our in vivo and ex vivo programs to develop product candidates addressing a broad range of diseases. As exemplified by our current programs, this approach will allow us and our partners to build a full-spectrum genome editing company, with a pipeline of products that can treat a broad range of genetic and oncological diseases.

View Our Pipeline

Overview

As a pioneer in the development of CRISPR/Cas9-based therapies, we are rapidly moving our development candidates towards the clinic so we can make them available to patients suffering severe and life-threatening disorders.

Our company’s unique strengths include our CRISPR/Cas9 system improvements, modular lipid nanoparticle delivery system and our determined focus on product development.

Learn About Our Mission

A Great Place to Work

Learn More
Menu